All News
Combination biologics in PsA: are we there yet?
Despite various and efficacious options for management of PsA there is still an unmet need for patients with inadequate responses to current therapies or difficult-to-treat disease. The role of dual biologic therapy targeting different inflammatory pathways has become an area of great interest in the field.
Read Article
Valentine RNL 2025 Review (2.14.2025)
Dr. Jack Cush reviews highlights from RheumNow Live 2025 held in Dallas, TX on Feb. 8-9, 2025.
Read Article
Obinutuzumab Efficacy in Active Lupus Nephritis
A phase 3, randomized controlled trial of an anti-CD20 monoclonal antibody, obinutuzumab, was shown to be effective and safe in patients with active lupus nephritis.
Read Article
Drug Naming Games (2.7.2025)
Dr. Jack Cush reviews the news, regulatory and journal reports from the past week on RheumNow.com.
Read Article
Granzyme - a major driver of inflammatory & autoimmune diseases
EurekAlert!
Our immune system is armed with an array of defenses designed to detect and eliminate harmful threats. One of its most powerful defense mechanisms is the complement system—a group of proteins that patrols our body, ever vigilant for signs of infection or injury.
Read Article
The POWER of #plaquenil
#Hydroxychloroquine works in #rheumatic #diseases by
Old answer
👇
Alters liposomal membranes 🤷♀️
NEW ANSWER
Inhibits TLR signalling 🔥
#RNL2025 Mary *Peggy Crow #SLE #systemic #lupus #erythematosus https://t.co/j2YQjVIpcy
Dr. John Cush RheumNow ( View Tweet)
#Benralizumab vs #Mepolizumab
both work for #EGPA
Which to use? 🤷♀️
perhaps some advantage of more steroid sparing w
Benralizumab?
? JAKi ?long acting #IL5i
#RNL2025 @RheumNow https://t.co/UkthHpNRIq
Janet Pope Janetbirdope ( View Tweet)
Obinutuzumab Efficacy in Active Lupus Nephritis
A phase 3, randomized controlled trial of an anti-CD20 monoclonal antibody, obinutuzumab, was shown to be effective and safe in patients with active lupus nephritis.
https://t.co/e1cDvJcC9g https://t.co/HUDd1ocAvc
Dr. John Cush RheumNow ( View Tweet)
ICYMI: Treatment of sclerosing skin disease:
-Progression: inflammation➡️sclerosis➡️ atrophy
-Existing therapies target inflammation not sclerosis-poorly developed ttx for sclerosis
-First aspect is determining disease state, depth of involvement, extracutaneous manifestations… https://t.co/lYQRW2yDRG https://t.co/DQZjYKS2Ks
Links:
Adela Castro AdelaCastro222 ( View Tweet)
Study of 702 pts who transitioned from PsO to PsA (median 9yrs) - no baseline differences in PsA pts who transitioned late (>9yrs); but on follow-up, the late group had lower Dz activity, less csDMARD use, but no difference in radiographic progression https://t.co/vwgfa5z6BE https://t.co/N1yUcrcR2o
Links:
Dr. John Cush RheumNow ( View Tweet)
-HS ttx👇
1. Lifestyle changes: smoking cessation, obesity.
2. Management of comorbidities.
3. 🔍HS- related autoimmune disorders.
4. FDA approved biologics:
-Adalimumab (PIONEER 1&2)
-Secukinumab (SUNRISE, SUNSHINE)
-Bimekizumab (BE HEARD 1&2)
"Theres no such… https://t.co/G5Voxrm3Kt https://t.co/dLGtoFZMd1
Links:
Adela Castro AdelaCastro222 ( View Tweet)
P2 Trial: DEU in PsA
Encouraging results for DCV 6 and 12 mg qd.
ACR20 63% for DCV 12 mg (p=0.0004)
Not yet FDA approved for PsA, only PsO
Pending P3
P2: DEU in SLE - PAISLEY
Improved SRI(4), CLASI-50 at w32
Merola
#RNL2025 @RheumNow https://t.co/RV7OPaZWjx
Links:
Eric Dein ericdeinmd ( View Tweet)
#RNL2025 @RheumNow
JAKi in DM:
@JuliePaikMD- 10 DM pts open label on JAKi. 7/10 improved from mod/severe to mild. In 96wk extension, 6 of 7 continued response
145 case reports for tofa, bari, ruxolitinib.
Role in helping calcinosis? Pruritu?
Brepocitinib (JAK1/TYK2i) study
Eric Dein ericdeinmd ( View Tweet)
Great graph from @AlexisOgdie on the effect of biologic treatment on PsA development in psoriasis. Obvious front-loading in those who need systemic therapy. But over time those who don't appear to develop more PsA @RheumNow @RNL2025 https://t.co/UxUZyKb0NA
Richard Conway RichardPAConway ( View Tweet)
FDA has approved Journavx (suzetrigine) 50 mg tablets, 1st in-class non-opioid analgesic, to treat moderate to severe acute pain in adults. Journavx reduces pain by targeting a pain-signaling pathway involving sodium channels in the peripheral nervous system, before pain signals… https://t.co/qjtr4yz8Ot https://t.co/RUZmLgsmTv
Dr. John Cush RheumNow ( View Tweet)
🏈Kick-off of @RheumNow w Jeff Curtis #RNL2025 🏈
AI in RA?
Can help with Rheum Boards Questions, though AI is not confident in answers
May not be better than paper charts for triage
Other roles: pt chatbot, AI scribe, research populations, generate DDx, consume guidelines https://t.co/X43DCmt0Ov
Links:
Eric Dein ericdeinmd ( View Tweet)
Can #AI help us determine the
👇
Right drug
At
Right time
Pipe dream?
Or to use #artificial #intelligence term
➡️ a #hallucination?
garbage in ➡️➡️garbage out
Most predictions of drug response are same: multimorbid multiRx failures
Nonadherent poverty #RNL25 @RheumNow https://t.co/70SRp8BnCl
Janet Pope Janetbirdope ( View Tweet)
Rituximab is FDA approved for treatment of moderate to severe pemphigus, but 20% may relapse in 1st Yr. Study of 87 pts shows the efficacy of repeat 6 mos RTX in A) those with persistent Dz activity and B) anyone w/ predictors of relapse (PDAI score, DSG1 or DSG3 abs)… https://t.co/IhqdGWVcdp https://t.co/MKhDpa5zHv
Dr. John Cush RheumNow ( View Tweet)
A 3rd Actemra biosimilar was approved by the FDA - Celltrion announced approval of its 7th biosimilar, Avtozma (CT-P47, tocilizumab-anoh); both IV & SCm for Rx of RA, GCA, pJIA, Still's dz & Covid-19. Joins other IL-6 biosimilars Tofidence (Biogen 10/23) & Tyenne (Frensius 3/24)… https://t.co/UtG9YOXUX2 https://t.co/j3LzG7beys
Dr. John Cush RheumNow ( View Tweet)
FDA has approved Journavx (suzetrigine) 50 mg tablets, 1st in-class non-opioid analgesic, to treat moderate to severe acute pain in adults. Journavx reduces pain by targeting a pain-signaling pathway involving sodium channels in the peripheral nervous system, before pain signals… https://t.co/xKy7JY7pPr https://t.co/VYrDMQcjHc
Dr. John Cush RheumNow ( View Tweet)
